In determining whether a next generation tobacco or nicotine product should be granted a U.S. marketing authorization, FDA are assessing:
If the BENEFIT of the product to adults who smoke outweighs the RISK of the product to those below the minimum legal age of sale.
So, how many people in the United States are using your tobacco and nicotine products and are they benefiting or at risk?
For each next generation tobacco and nicotine product included in the study, TPPS data can quantify:
This data is critical in enabling FDA to evaluate the overall impact of the product on the whole U.S. population.
The next wave of TPPS data collection is scheduled for May 2025.
To secure inclusion for your brand’s products contact the TPPS Study Lead:
Dr Andrea Patton Ph.D.
email: [email protected]
JOIN OUR MAILING LIST
Be the first to hear about exhibitors, speakers and what's on at our upcoming events.
Please note that this is not a show registration form. To register for FREE for WVS Dubai, please use the pink Register to attend button at the top of the page!